WO2001096372A2 - Zinc transporters proteins and their use in medicinal preparations - Google Patents
Zinc transporters proteins and their use in medicinal preparations Download PDFInfo
- Publication number
- WO2001096372A2 WO2001096372A2 PCT/GB2001/002597 GB0102597W WO0196372A2 WO 2001096372 A2 WO2001096372 A2 WO 2001096372A2 GB 0102597 W GB0102597 W GB 0102597W WO 0196372 A2 WO0196372 A2 WO 0196372A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- proteins
- consensus
- zinc
- regions
- polypeptide
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 5
- 108091006550 Zinc transporters Proteins 0.000 title description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 77
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 45
- 229920001184 polypeptide Polymers 0.000 claims abstract description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 239000011701 zinc Substances 0.000 claims abstract description 25
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 22
- 230000007987 cellular zinc ion homeostasis Effects 0.000 claims abstract description 19
- 108091035707 Consensus sequence Proteins 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 238000012360 testing method Methods 0.000 claims abstract description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 6
- 238000003745 diagnosis Methods 0.000 claims abstract description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 4
- 230000006907 apoptotic process Effects 0.000 claims description 28
- 102000005741 Metalloproteases Human genes 0.000 claims description 14
- 108010006035 Metalloproteases Proteins 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 230000001640 apoptogenic effect Effects 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 abstract description 7
- 239000000262 estrogen Substances 0.000 abstract description 6
- 235000018102 proteins Nutrition 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 45
- 235000014304 histidine Nutrition 0.000 description 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 10
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 108010078791 Carrier Proteins Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000032258 transport Effects 0.000 description 7
- 102000004310 Ion Channels Human genes 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- CVRXLMUYFMERMJ-UHFFFAOYSA-N N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CCN(CC=1N=CC=CC=1)CC1=CC=CC=N1 CVRXLMUYFMERMJ-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- ULHRKLSNHXXJLO-UHFFFAOYSA-L Yo-Pro-1 Chemical compound [I-].[I-].C1=CC=C2C(C=C3N(C4=CC=CC=C4O3)C)=CC=[N+](CCC[N+](C)(C)C)C2=C1 ULHRKLSNHXXJLO-UHFFFAOYSA-L 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000036436 Metzincins Human genes 0.000 description 2
- 108091007161 Metzincins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000036435 Zincins Human genes 0.000 description 2
- 108091007139 Zincins Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000685848 Homo sapiens Zinc transporter ZIP6 Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100023144 Zinc transporter ZIP6 Human genes 0.000 description 1
- -1 Zn2+ ions Chemical class 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Definitions
- This invention relates to the field of treatment and diagnosis of oncological and neurological disease and, in particular, though not exclusively, it relates to the use of proteins in cancer treatment and diagnosis.
- LIN-1 and other proteins form the basis of a new family with the potential to bind and transport Zn 2+ across cell membranes and it is an object of the present invention to provide methods of using this finding in the medical, especially oncological, field.
- FIG. 1 shows the sequences of the identified proteins of the LIN-1 family. Other proteins may be identified by following the methods described herein. The sequences have been aligned, with spaces (dashes) inserted where necessary to allow a more clear alignment of consensus regions. The bars (I to NIII) indicate the approximate locations of the assigned transmembrane regions, whilst the "+" signs indicate the approximate location of the metalloprotease motif.
- LIN-1 is referred to in Figure 1 as U41060; the terms are used interchangeably herein.
- one aspect of the present invention provides the use of a polypeptide comprising one or more of the consensus regions of the proteins shown in Figure 1, or a functional homologue thereof, in the preparation of a medicament for the treatment of a disease selected from those involving disorders of zinc homeostasis.
- the consensus regions are defined by the stretches of matching or similar residues when the sequences are aligned with each other.
- 'similar' or 'similarity' refer to the similarity of amino acid residues as defined according to the following scheme: aromatic residues, F, H W and Y; charged residues, D, E, H, K and R; hydrophobic residues A, C, F, G, H, I, L, M, N, and Y; aliphatic residues I, L and N; tiny residues A, G and S; polar residues D, E, H, K, ⁇ , Q, R, S and T; small residues A, C, S, T, D, ⁇ , N, G and P;
- a functional homologue is one having the ability to bind and transport Zn 2+ across cell membranes and comprising the metalloprotease motif shown in Figure 1.
- the polypeptide or homologue comprises two or more such consensus regions.
- the polypeptide or homologue preferably includes at least one of the regions I-NIII.
- the polypeptide or homologue comprises consensus regions N, NI and the metalloprotease motif. More preferably, the polypeptide or homologue has a degree of similarity of 30 to 90% with the proteins of Figure 1 or 70-90% with the consensus regions.
- the polypeptide or homologue has the sequence of one of the proteins shown in Figure 1.
- a further aspect of the present invention provides the use of a nucleic acid molecule encoding a polypeptide comprising one or more of the consensus regions of the proteins shown in Figure 1, or a functional homologue thereof, in the preparation of a medicament for the treatment of a disease selected from those involving disorders of zinc homeostasis.
- the disease may be breast cancer, especially oestrogen responsive metastatic breast cancer.
- the polypeptide does not have the same sequence as LIN-1 or U41060.
- the invention provides a method of selecting compounds for use in the treatment of a disease selected from those involving disorders of zinc homeostasis, the method comprising determining the effect of a test compound on a function of a polypeptide comprising one or more of the consensus regions of the proteins shown in Figure 1, or a functional homologue thereof.
- the compounds may be selected for use in the treatment of breast cancer, especially oestrogen-responsive metastatic breast cancer. Accordingly, in yet another aspect, the invention provides compounds for the treatment of a
- the function of the protein to be affected by the test compounds is preferably its zinc
- the testing is preferably performed in cell culture. Suitable methods
- the invention provides recombinant proteins including at least one of
- the consensus sequence includes at least one of the
- the consensus sequence also includes the
- the consensus sequence comprises region N, the metalloprotease motif and region NI.
- a recombinant protein is one which is not endogenously produced but is produced by
- the consensus sequence includes that corresponding with
- the invention also provides an antibody molecule having affinity for one or more of the proteins listed in Figure 1.
- the antibody molecule has affinity for one or more of the consensus sequences described above.
- the term antibody molecule includes antigen-binding fragments such as Fv, Fab and Fab'.
- the invention also provides a kit of antibody molecules directed against at least two different proteins selected from those listed in Figure 1, or against at least two of their consensus sequences as described above.
- the invention provides a method for identifying proteins involved in zinc homeostasis, the method comprising comparing a test protein with one or more of the proteins listed in Figure 1, wherein the involved proteins are identified by having similarity with the sequences given in Figure 1.
- the test protein sequences are compared with two, more preferably five or more, sequences selected from Figure 1.
- Also provided is a method of diagnosis of a zinc homeostasis-related condition in a subject comprising contacting a sample from that subject with an antibody molecule of the present invention and measuring the binding of that antibody to the sample.
- a method of treatment of a zinc homeostasis-related condition in a subject comprising contacting the subject with an antibody molecule of the present invention.
- the invention provides a method of treatment of a disease selected from those involving disorders of zinc homeostasis, the method comprising the administration, to a subject in need of such treatment, of a therapeutically effective amount of a polypeptide comprising one or more of the consensus regions of the proteins listed in Figure 1, or a functional homologue thereof.
- the polypeptide or homologue comprises at least two of those consensus regions.
- the disease may be breast cancer,
- the invention provides a method of treatment of a disease selected from
- nucleic acid to a subject in need of such treatment, of a therapeutically effective amount of a nucleic acid
- Apoptosis programmed cell death, a physiological process for killing cells, is critical for
- present invention may also be those involving disorders of apoptosis.
- the invention also be those involving disorders of apoptosis.
- the invention also be those involving disorders of apoptosis.
- polypeptide or homologue preferably comprises two or more consensus regions.
- the polypeptide or homologue may include at least one of the regions I to NIII and may comprise the whole sequence of a protein selected from Figure 1.
- Figure 1 shows the sequences of the identified proteins of the LIN-1 family, as described above;
- Figure 2 shows the individual, non-aligned sequences of the proteins listed in Figure 1, together with their species of origin and alternative accession numbers;
- Figure 3 is a schematic diagram of the domain organisation of the LIN-1 family of proteins
- Figure 4 shows the results of an experiment looking at multimeric complex formation in two of the proteins listed in Figure 1.
- CAA20238 and Q 15043 were expressed in CHO cells and then analysed by SDS-PAGE under both reducing (R) and non-reducing ( ⁇ R) conditions;
- Figure 5 is a schematic diagram of the zinc-binding environment of the metzincins (18), altered to suggest potential zinc co-ordinating residues in the metalloprotease motif of the LIV-l family. Shaded residues are known to co-ordinate zinc, square boxes represent conserved residues unique to the LIN-1 family and dotted lines suggest zinc co-ordination ability; Figure 6 shows the results of experiments looking at cellular import of zinc in cells
- Figure 8 shows the effect of some of the LIN-1 family members on apoptosis. The results
- Figure 9 shows the effect of the apoptotic changes of Figure 8 on cell growth curves.
- Figure 10 shows a fluorescence micrograph of apoptosis in cells expressing a LIN-1 family
- D ⁇ A constructs for expression in CHO cells were engineered by PCR with primers F2A5 (5'): CCCATCGGAT CCGGCACAAT GGCCAGAGGC CTGGGG, and F2A3 (3'): CCCATCCTTA TCGTCATCGT CGTACAGATC CTCAAGGTGG GCAATCAGCA CC for CAA20238, and FamA5 (5'): CCCCACACCA TGAAGCTGCT GCTGCTGCAC CC, and famaA3 (3'): CCCATCCTTC CTTTCATCCT C, for Q15043, and 5'-CCCATCGGAT CCGGCACAAT GGCGAGGAAG TTATC-3' and 5'-GAAATTTATA CGAAACACGA TTTTATG-3' for LIV-l.
- CHO cells plated at 1.1 x lOVml the previous day were transiently transfected with plasmid using Transfast (Promega) and harvested between 22-40 hours. Mock-transfected cells are designated CHO and cells transfected with the LacZ gene and expressing the control cytosolic protein ⁇ -Galactosidase are designated LacZ.
- Transfected CHO cells were harvested with 3mM EDTA in PBS and resuspended at lxlOVml in KRH buffer or medium. Cells were incubated with or YO-PRO-1 (Molecular Probes) and 1.5 ⁇ M propidium iodide for 20 mins on ice in KRH or newport green diacetate (Molecular Probes) for lhour in medium at 37°C. For zinc analysis, 25 ⁇ M Zinc chloride and/or lO ⁇ M cell permeant zinc chelator TPEN (Molecular Probes) were added for 15mins prior to testing. Cells were resuspended in KRH prior to fluorescent measurements using a Becton Dickinson Flow Cytometer.
- Second is the presence of a new well-conserved motif spanning 74 residues (shown by bold dashes in Figure 1) and including the hydrophobic transmembrane domains V and VI. Adjacent to this latter domain and included in the new motif is the consensus sequence of the catalytic Zri ⁇ -binding site of the zincin and PDF groups of metalloproteases, HEXXHXXG, which is essential for their activity (13-15).
- the LIV-l family motif contains novel conserved proline and glutamic acid residues (underlined), HEXPHEXGD, and is adjacent to a transmembrane domain (Figure 1). Both are previously unprecedented in mammals.
- histidine-rich repeats similar to those in zinc transporters (HX) n (10). These regions are important for binding and transporting Zn 2+ (21) and are more plentiful in most of the new family than in other Zn 2+ transporters (see Table 1, below, showing a comparison of histidine-rich repeats in 30 of the new family of proteins (Table 1 A) with those in the known zinc transporters (Table IB)). It is noteworthy that the occurrence of these histidine-rich repeats in this new family are predominantly in three different areas of the sequence, the N-terminus, the second transmembrane loop and the third transmembrane loop (Figs 1 and 3). This positions them uniquely on opposing membrane sides unlike conventional zinc transporters.
- the new family of proteins can increase intracellular zinc
- Zn 2+ is a co-factor of over 300 enzymes, involved in protein, nucleic acid, carbohydrate and lipid metabolism, as well as the control of gene transcription, growth, development and differentiation (3). Zn 2+ deficiency stunts growth and causes serious metabolic disorders (4) while increased levels of Zn 2+ can have a beneficial effect on cell growth (33 .
- Figure 6 shows the differences of intracellular zinc content between CHO cells expressing a family member and control cells as measured by loading cells with Newport Green Diacetate. Approximately 20-25% of control cells had high levels of intracellular zinc compared with 40-45% in test samples. These were transient transfections which routinely transfected only 20-30% of cells, suggesting that cells expressing the test proteins have higher intracellular zinc levels. The addition of 25 ⁇ M extracellular zinc increased the number of cells with high intracellular zinc further without altering the controls. This result indicates that the transfected cells import the extracellular zinc.
- Figure 7 shows a different experiment where addition of 25 ⁇ M extracellular zinc causes a 75-90% increase in the number of transfected test cells with increased intracellular zinc levels within 15 mins, whereas the control cells showed only small changes.
- Addition of the cell-permeant zinc chelator TPEN for a further 15min reversed this effect for LIV-l and CAA20238.
- the addition of TPEN to Q15043 had little effect, suggesting that Q15043 may use a different mechanism.
- the new family of proteins can increase cell apoptosis
- Apoptosis programmed cell death, a physiological process for killing cells, is critical for the normal development and function of multicellular organisms, aberrations of which have been linked to a variety of diseases (27). Abnormalities of apoptosis can contribute to a number of diseases such as cancer (28), autoimmunity (29) and degenerative disorders (30). Signalling for apoptosis occurs through multiple pathways originating both inside and outside the cell. Amongst the earliest changes in cells undergoing apoptosis is plasma membrane blebbing (31) and a loss of membrane phospholipid asymmetry, resulting in the exposure of phosphatidylserine at the surface of the cell (32).
- CHO cells expressing the recombinant proteins were tested for apoptosis associated with loss of membrane potential by incubating with the fluorescent dye YO-PRO-1, which enters apoptotic cells. It is clear from Figure 8 that 20% more cells transfected with CAA20238 and 10% more cells transfected with Q 15043 are positive for apoptosis. However, cells expressing U41060 exhibit the same amount of apoptosis as the controls, presumably due to the low expression level of LIV-l in cells.
- Oestrogen-regulated LIV-l has been implicated in metastatic breast cancer (2).
- the other proteins may have a role in cancer and/or other diseases.
- Multiple human tissue array analysis of LIV-l, CAA20238 and Q 15043 suggest that they are predominantly present in hormonal tissues.
- BAA86579 occurs principally in brain (22) where aberrant Zn ⁇ levels have been linked to apoptosis and neuronal disease (23). These proteins form an exciting new family, which have the potential to control Zn ⁇ homeostasis in cells, failure of which has been linked with cancer and disease (24, 25).
- the LIV-l family of transmembrane proteins are capable of causing Zn 2+ -related apoptosis. These sequences have a motif HEXPHEXGD fitting the consensus sequence for the Zn 2+ -binding site of the PDF and zincins group of metalloproteases (21) yet containing unique proline and glutamic acid residues (bold) previously unprecedented in an HEXXH motif. This motif forms part of a highly conserved region of 74 residues including two potential transmembrane domains (Fig 1), which are suggested to be the signature for this new family.
- LIV-l has been implicated in metastatic breast cancer, yet we have observed its expression to be over 10,000 fold reduced compared to the other family member proteins examined so far suggesting a possible growth advantage (see figure 9) to breast cancer cells. These proteins have the potential to control apoptosis of cells by the transport of intracellular Zn 2+ . This function has important implications not only for the growth control of healthy cells but also for a number of significant diseases such as cancer and neurodegeneration. An added bonus for future drug intervention is the fact that Zn 2+ is relatively non-toxic to cells, therefore offering a potential method of therapy.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001264099A AU2001264099A1 (en) | 2000-06-13 | 2001-06-13 | Zinc transporters |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0014411.3 | 2000-06-13 | ||
GB0014411A GB0014411D0 (en) | 2000-06-13 | 2000-06-13 | Zinc transporters |
GB0014493.1 | 2000-06-14 | ||
GB0014493A GB0014493D0 (en) | 2000-06-14 | 2000-06-14 | Zine transporters |
US21634900P | 2000-07-05 | 2000-07-05 | |
US60/216,349 | 2000-07-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001096372A2 true WO2001096372A2 (en) | 2001-12-20 |
WO2001096372A3 WO2001096372A3 (en) | 2002-05-16 |
Family
ID=27255758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/002597 WO2001096372A2 (en) | 2000-06-13 | 2001-06-13 | Zinc transporters proteins and their use in medicinal preparations |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001264099A1 (en) |
WO (1) | WO2001096372A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005063301A1 (en) * | 2003-12-26 | 2005-07-14 | Toshio Hirano | Emt inducer |
AU2003291625B2 (en) * | 2002-09-16 | 2009-10-08 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US7916304B2 (en) | 2006-12-21 | 2011-03-29 | Howard Hughes Medical Institute | Systems and methods for 3-dimensional interferometric microscopy |
US8313745B2 (en) | 1999-03-15 | 2012-11-20 | Abbott Biotherapeutics Corp. | Compositions against cancer antigen LIV-1 and uses thereof |
US8591863B2 (en) | 2003-01-29 | 2013-11-26 | Abbvie Biotherapeutics Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
WO2014186587A1 (en) * | 2013-05-15 | 2014-11-20 | Syracuse University | Methods and systems for zinc delivery using intrinsic factor or haptocorrin |
USRE48959E1 (en) | 2010-12-06 | 2022-03-08 | Seagen Inc. | Humanized antibodies to LIV-1 and use of same to treat cancer |
US11325980B2 (en) | 2016-03-15 | 2022-05-10 | Seagen Inc. | Combination therapy using a LIV1-ADC and a chemotherapeutic |
-
2001
- 2001-06-13 WO PCT/GB2001/002597 patent/WO2001096372A2/en active Application Filing
- 2001-06-13 AU AU2001264099A patent/AU2001264099A1/en not_active Abandoned
Non-Patent Citations (3)
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8313745B2 (en) | 1999-03-15 | 2012-11-20 | Abbott Biotherapeutics Corp. | Compositions against cancer antigen LIV-1 and uses thereof |
AU2003291625B2 (en) * | 2002-09-16 | 2009-10-08 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
AU2010200063B2 (en) * | 2002-09-16 | 2011-10-20 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US8906342B2 (en) | 2003-01-29 | 2014-12-09 | Abbvie Biotherapeutics Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
US8591863B2 (en) | 2003-01-29 | 2013-11-26 | Abbvie Biotherapeutics Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
WO2005063301A1 (en) * | 2003-12-26 | 2005-07-14 | Toshio Hirano | Emt inducer |
US8780442B2 (en) | 2006-12-21 | 2014-07-15 | Howard Hughes Medical Institute | Optical interfering apparatus |
US7916304B2 (en) | 2006-12-21 | 2011-03-29 | Howard Hughes Medical Institute | Systems and methods for 3-dimensional interferometric microscopy |
US9127925B2 (en) | 2006-12-21 | 2015-09-08 | Howard Hughes Medical Institute | Method of 3-dimensional imaging of activated samples |
US9482512B2 (en) | 2006-12-21 | 2016-11-01 | Howard Hughes Medical Institute | Methods for 3-dimensional interferometric microscopy |
USRE48959E1 (en) | 2010-12-06 | 2022-03-08 | Seagen Inc. | Humanized antibodies to LIV-1 and use of same to treat cancer |
WO2014186587A1 (en) * | 2013-05-15 | 2014-11-20 | Syracuse University | Methods and systems for zinc delivery using intrinsic factor or haptocorrin |
US9505825B2 (en) | 2013-05-15 | 2016-11-29 | Syracuse University | Methods and systems for zinc delivery using intrinsic factor or haptocorrin |
US11325980B2 (en) | 2016-03-15 | 2022-05-10 | Seagen Inc. | Combination therapy using a LIV1-ADC and a chemotherapeutic |
Also Published As
Publication number | Publication date |
---|---|
AU2001264099A1 (en) | 2001-12-24 |
WO2001096372A3 (en) | 2002-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nava et al. | Desmoglein-2: a novel regulator of apoptosis in the intestinal epithelium | |
US9605042B2 (en) | Compositions and methods related to tauopathy | |
JP2006149394A (en) | beta-SECRETASE, ANTIBODY AGAINST beta-SECRETASE, AND ASSAY FOR DETECTING beta-SECRETASE INHIBITION | |
BG106907A (en) | Nogo receptor-mediated blockade of axonal growth | |
US20110230364A1 (en) | Methods for identifying modulators of apoptosis | |
KR102186218B1 (en) | Erythroferrone and erfe polypeptides and methods of regulating iron metabolism | |
Nehmé et al. | The expression pattern of the Na+ sensor, Nax in the hydromineral homeostatic network: a comparative study between the rat and mouse | |
US20090306192A1 (en) | BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases, and for modulation of cell survival and/or death | |
Volpina et al. | Synthetic fragment of receptor for advanced glycation end products prevents memory loss and protects brain neurons in olfactory bulbectomized mice | |
ES2306672T3 (en) | METHOD OF SCREENING FOR CANDIDATE DRUGS. | |
WO1995026506A1 (en) | Methods for detecting calpain activation and indentifying calpain inhibitors | |
JP2000509967A (en) | Peptides from soluble forms of acetylcholinesterase active as calcium channel modulators | |
Penniston et al. | Plasma membrane Ca2+ pump: recent developments | |
JP2001504681A (en) | Inhibition of protein interactions | |
WO2001096372A2 (en) | Zinc transporters proteins and their use in medicinal preparations | |
WO2005093057A1 (en) | Truncated dance, dance complex and method of using these | |
CA2590751A1 (en) | Polynucleotides and polypeptide sequences involved in the process of bone remodeling | |
US5905146A (en) | DNA binding protein S1-3 | |
AU2012272550B2 (en) | Prevention and treatment of acute inflammatory conditions | |
CN113365661A (en) | CNX/ERP57 inhibitors for the treatment or prevention of cancer | |
US7767417B2 (en) | Prenyl-electrostatic switch, and methods of use | |
CN108144060A (en) | One kind treats the drug and its screening technique for the disease that monocyte chemoattractant protein-1 participates in by regulating and controlling YB-1 phosphorylations | |
JP2003523723A (en) | Hermansky-Padrack syndrome protein-interacting proteins and methods of use | |
Wolff | Investigation of the protective efficacy of α-synuclein-specific antibodies in a novel neuronal cell model for α-synucleinopathies | |
Tasnim et al. | Alpha-synuclein fragments trigger distinct aggregation pathways |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |